Application of thymosin or derivative thereof and medicine for treating pleasant sensation deficiency type depression

Abstract

The invention belongs to the field of pharmacology, discloses an application of thymosin or a derivative thereof and a medicine for treating pleasant sensation deficiency type depression, and particularly discloses an application of thymosin or a derivative thereof in preparation of a medicine for treating pleasant sensation deficiency type depression. The invention further discloses a pharmaceutical composition for treating pleasant sensation deficiency type depression, and the pharmaceutical composition comprises a therapeutically effective amount of thymosin or a derivative thereof. According to the invention, systemic administration of thymosin or a derivative thereof, particularly thymosin beta4 or a derivative thereof, is safe, has a good curative effect on pleasant sensation deficiency type depression, and is tolerated by animals including human beings.

Description

technical field [0001] The application relates to the field of pharmacy, specifically, the application of thymosin and its derivatives and the medicine for treating anhedonia type depression. Background technique [0002] It is well known that life stress, physical illness, or psychological stress are the triggers for many mental illnesses, including depression and anhedonia. Professor Willer successfully confirmed in 1987 that chronic unpredictable stress can significantly cause animal behaviors such as anhedonia, hopelessness and anxiety, and has been recognized internationally. Stress stimulates specific limbic brain regions and the HPA axis. Under continuous stress stimulation, the secretion of a large amount of glucocorticoids leads to the conversion of brain neurotransmitters (such as 5-HT, DA, NE, etc.), thereby reducing the availability of neurotransmitters in the brain, and inducing a series of psychological disorders such as depression and anhedonia. and mental i...

AI Technical Summary

Problems solved by technology

The reduction of DA levels also affects the levels of DOPAC and HVA and thus affects the occurrence of anhedonia

The imbalance of the three systems of 5-HT energy, NE energy and DA energy may lead to the occurrence of anhedonia, and there may also be a disturbance in the balance of the conversion between DA and 5-HT in the central nervous system

[0004] At present, the drugs used to treat anhedonia-type depression are mainly monoamine reuptake inhibitors used to treat depression, such as bupropion, duloxetine, fluoxetine, etc., but these drugs It can cause severe cardiovascular side effects such as tachycardia, drowsiness, constipation, dysuria, urinary retention, and overdose can cause acute poisoning or even death

Images